Clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases
Clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases. Its pipeline of brain-penetrant kinase inhibitors aims to restore cellular autophagy and address neuroinflammation, toxic protein buildup, and vascular damage. Its lead asset is a transdermal formulation of nilotinib, with programs targeting dementia with Lewy bodies, Alzheimer’s disease, ALS, Parkinson’s disease, and frontotemporal dementia.